U.S. markets close in 6 hours 25 minutes

Bruker Corporation (BRKR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
73.07+0.26 (+0.35%)
As of 9:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close72.81
Open72.77
Bid70.86 x 1000
Ask75.11 x 1000
Day's Range72.93 - 73.24
52 Week Range36.82 - 75.82
Volume20,601
Avg. Volume564,670
Market Cap11.071B
Beta (5Y Monthly)1.30
PE Ratio (TTM)55.31
EPS (TTM)1.32
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & Yield0.16 (0.22%)
Ex-Dividend DateMay 28, 2021
1y Target Est73.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
    Zacks

    Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View

    Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.

  • Bruker Updates FY21 Guidance, Issues Medium Term Outlook
    Benzinga

    Bruker Updates FY21 Guidance, Issues Medium Term Outlook

    View more earnings on BRKRSee more from BenzingaClick here for options trades from BenzingaCyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol CycloAmneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day
    Business Wire

    Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day

    BILLERICA, Mass., Jun 17, 2021--At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company’s strategy and Project Accelerate 2.0 initiatives, including the Company’s potential high-growth opportunities in the areas of proteomics and spatial biology. Bruker will also update its fiscal year 2021 guidance and will discuss its medium term financial outlook through 2024.